Figure 5个  Table 2个
    • Compounds CC50a H1N1 H3N2
      MDCK HeLa EC50b SIc EC50 SI
      Acids extract 139.8 ± 9.3 143.3 ± 6.0 15.6 ± 1.5 8.9 5.6 ± 0.6 24.9
      Flavonoids extract 82.4 ± 0.8 76.9 ± 1.4 17.2 ± 3.8 4.8 14.1 ± 2.5 5.9
      Total extract 350.0 ± 14.5 178.1 ± 2.7 14.3 ± 7.0 25.2 7.4 ± 1.0 48.6
      Acids-flavonoids 88.3 ± 3.9 116.5 ± 2.9 3.8 ± 0.3 23.5 4.1 ± 0.5 21.8
      Oseltamivir >500 2.6 ± 0.1 >192 3.1 ± 0.1 >161
      Ribavirin 13.7 3.5 ± 0.1 3.9 NDd ND
      The results were the mean ± S.D.of three independent experiments.
      aConcentration of drugs required to reduce the viability of normal MDCK cells by 50% (μg/mL).
      bConcentration of drugs required to improve the viability of influenza virus-infected cells by 50% (μg/mL).
      cSelectivity index, CC50/EC50.
      dNot determined.

      Table 1.  Cytotoxicity and antiviral activity of honeysuckle extracts.

    • NA IC50a ± SD (μg/mL)
      Acids extract Flavonoids extract Total extract Acids-flavonoids
      H1N1 112.3 ± 17.7 90.9 ± 8.6 305.1 ± 23.7 100.1 ± 11.4
      H3N2 332.6 ± 34.5 196.0 ± 23.4 947.3 ± 39.5 203.8 ± 9.9
      H5N1 78.8 ± 5.5 54.7 ± 3.4 283.9 ± 29.0 63.8 ± 0.6
      H7N9 55.9 ± 5.1 24.7 ± 2.3 170.0 ± 5.2 35.2 ± 3.1
      H1N1-H275Y 150.4 ± 13.6 108.4 ± 17.0 350.1 ± 36.9 125.7 ± 14.7
      H7N9-R294K 80.1 ± 6.3 44.1 ± 5.4 291.2 ± 26.2 53.1 ± 6.0
      The results were the mean ± S.D. of three independent experiments.
      aConcentration of drugs required to reduce the activity of neuraminidase by 50%.

      Table 2.  IC50 of honeysuckle extracts against neuraminidase activity of influenza A virus.